Neuralstem Inc (CUR) Jumps 19.12% on February 19

Equities Staff |

Neuralstem Inc (CUR) was among the biggest gainers on the Russell 2000 for Friday February 19 as the stock popped 19.12% to $1.01, representing a gain of $0.1621 per share. Some 611,942 shares traded hands on 936 trades, compared with an average daily volume of 311,720 shares out of a total float of 91.79 million. The stock opened at $0.85 and traded with an intraday range of $1.04 to $0.85.

After today's gains, Neuralstem Inc reached a market cap of $92.71 million. Neuralstem Inc has had a trading range between $3.92 and $0.52 over the last year, and it had a 50-day SMA of $0.91 and a 200-day SMA of $1.37.

Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.

Neuralstem Inc is based out of Germantown, MD and has some 31 employees. Its CEO is I. Richard Garr.

For a complete fundamental analysis analysis of Neuralstem Inc, check out Equities.com’s Stock Valuation Analysis report for CUR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Wealthfront

Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…

Spotify

Spotify is a online music service offering providing digital content from a range of record labels and artists. Users can browse through the interface by artist, album, genre, playlist, record…